G
Ganeden Biotech
Science-backed probiotic ingredient for fortifying foods and beverages with digestive and immune health benefits
About Ganeden Biotech
GanedenBC30, a brand under Kerry's nutrition and wellness portfolio, specializes in providing a spore-forming probiotic ingredient known as Bacillus coagulans GBI-30, 6086. This probiotic is designed to remain viable through various manufacturing processes and the acidic environment of the stomach, making it ideal for fortifying everyday foods, beverages, and companion animal products. The company operates in the functional food and beverage market, targeting manufacturers looking to enhance their products with digestive and immune health benefits. GanedenBC30 generates revenue by supplying this specialized probiotic ingredient to product manufacturers, supported by over 25 published research papers validating its efficacy. The business model focuses on B2B relationships, providing a science-backed, hardy probiotic solution that meets consumer demand for health-focused products.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Oct 2017 | $0 | — | Kerry | — |
| EARLY VC✓Equity / VC | Nov 2007 | $12M | $48M | DSM Venturing · Capital Resource Partners · DSM | — |
Growth signals
Latest recorded traffic for Ganeden Biotech is 480 monthly website visits. Ganeden Biotech's team grew 0% over the past year.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Ganeden Biotech in the Mayfield Heights ecosystem
The Ganeden Biotech office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Capital Resource Partners
DSM- DVDSM Venturing
Other known investors1 additional known investor
Kerry
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ganeden Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ganeden Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.


